Skip to main content
GLUE
NASDAQ Life Sciences

Monte Rosa的MRT-2359进入二期临床试验，用于前列腺癌，获得强生公司的阿帕鲁胺供应

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$16.4
Mkt Cap
$1.221B
52W Low
$3.5
52W High
$25.77
Market data snapshot near publication time

summarizeSummary

Monte Rosa Therapeutics宣布与Johnson & Johnson签署了一项临床供应协议，以评估其实验性药物MRT-2359与强生的ERLEADA（阿帕鲁胺）联合使用，用于转移性去势抵抗性前列腺癌（mCRPC）的治疗。该协议促进了计划于2026年第三季度启动的二期临床试验，重点关注具有AR基因突变的患者。该公司指出，在正在进行的一期/二期临床试验中观察到令人信服的临床活性，表明这种联合治疗方法具有显著的希望，并可能使该项目在未来注册性研究中取得进展。这代表着Monte Rosa的主要管道资产取得了一项重大积极进展，推进了其发展，并为关键的联合治疗提供了机会。交易员将监测二期临床试验的启动和随后的数据发布。

在该公告发布时，GLUE的交易价格为$16.40，交易所为NASDAQ，所属行业为Life Sciences，市值约为$12.2亿。 52周交易区间为$3.50至$25.77。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed GLUE - Latest Insights

GLUE
Mar 17, 2026, 7:14 AM EDT
Filing Type: 10-K
Importance Score:
9
Monte Rosa Therapeutics Secures Substantial Capital, Extends Runway to 2029, and Advances Clinical Pipeline
Sentiment: Positive
View Wiseek Article
GLUE
Mar 17, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Monte Rosa Therapeutics Secures $345M Financing, Extends Cash Runway into 2029 Amidst Pipeline Advancements
Sentiment: Positive
View Wiseek Article
GLUE
Mar 17, 2026, 7:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Monte Rosa Therapeutics' Q4 Collaboration Revenue Plummets 95% to $2.78M
Sentiment: Negative
View Wiseek Article
GLUE
Mar 16, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Monte Rosa's MRT-2359 Enters Phase 2 for Prostate Cancer with J&J Apalutamide Supply
Sentiment: Positive
View Wiseek Article
GLUE
Feb 11, 2026, 4:36 PM EST
Filing Type: S-3ASR
Importance Score:
8
Registers New $100M At-The-Market Offering for Capital Raises
Sentiment: Negative
View Wiseek Article
GLUE
Jan 09, 2026, 4:32 PM EST
Filing Type: 8-K
Importance Score:
8
Monte Rosa Therapeutics Prices $300M Public Offering, Extending Cash Runway into 2029
Sentiment: Neutral
View Wiseek Article
GLUE
Jan 09, 2026, 4:31 PM EST
Filing Type: 424B5
Importance Score:
8
Monte Rosa Therapeutics Announces $300M Public Offering to Fund Clinical Programs and Extend Cash Runway
Sentiment: Neutral
View Wiseek Article
GLUE
Jan 09, 2026, 4:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Versant Funds Significantly Reduce Stake in Monte Rosa Therapeutics
Sentiment: Negative
View Wiseek Article
GLUE
Jan 07, 2026, 4:17 PM EST
Filing Type: 8-K
Importance Score:
7
Monte Rosa Therapeutics Terminates At-The-Market Equity Offering Program
Sentiment: Positive
View Wiseek Article
GLUE
Jan 07, 2026, 4:07 PM EST
Filing Type: 424B5
Importance Score:
8
Monte Rosa Therapeutics Announces $200M Offering and Positive Phase 1 Data for MRT-8102
Sentiment: Neutral
View Wiseek Article